EyePoint Pharmaceuticals, Inc.EYPT
| Jun 30,
2012 | Jun 30,
2013 | Jun 30,
2014 | Jun 30,
2015 | Jun 30,
2016 | Jun 30,
2017 | Jun 30,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Product | - | - | - | - | - | - | - | 17 | 21 | 35 | 40 |
|---|
| License And Collaboration Agreement | - | - | - | - | - | - | - | 1 | 12 | 1 | 0 |
|---|
| Royalty | - | - | - | - | - | - | 2 | 2 | 2 | 1 | 1 |
|---|
| Revenues | 4 | 2 | 3 | 27 | 2 | 8 | 3 | 20 | 34 | 37 | 41 |
|---|
| Cost Of Sales Excluding Amortization Of Acquired Intangible Assets | - | - | - | - | - | - | - | 3 | 6 | 8 | 8 |
|---|
| Research and development | 7 | 7 | 10 | 12 | 14 | 15 | 16 | 15 | 17 | 29 | 50 |
|---|
| Sales and marketing | - | - | - | - | - | - | 2 | 30 | 25 | 28 | 26 |
|---|
| General and administrative | 7 | 7 | 7 | 8 | 9 | 11 | 12 | 18 | 21 | 26 | 35 |
|---|
| Amortization of acquired intangible assets | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 |
|---|
| Impairment of acquired intangible assets | 15 | - | - | - | - | - | - | - | - | - | 21 |
|---|
| Total operating expenses | 29 | 14 | 17 | 20 | 23 | 26 | 29 | 68 | 72 | 92 | 141 |
|---|
| Loss from operations | -25 | -12 | -13 | 6 | -22 | -19 | -26 | -48 | -37 | -55 | -100 |
|---|
| Interest and other income, net | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
|---|
| Interest expense | - | - | - | - | - | - | 1 | 6 | 7 | 5 | 3 |
|---|
| (Loss) gain on extinguishment of debt | - | - | - | - | - | - | - | -4 | -1 | 2 | -2 |
|---|
| Total other expense, net | 0 | 0 | 0 | 0 | - | - | - | -9 | -8 | -3 | -3 |
|---|
| Net loss | -25 | -12 | -13 | 6 | -22 | -18 | -53 | -57 | -45 | -58 | -102 |
|---|
| Earnings Per Share, Basic | -1.19 | - | - | 0.22 | -0.68 | -0.52 | - | - | - | - | -2.74 |
|---|
| Earnings Per Share, Diluted | -1.19 | - | - | 0.21 | -0.68 | -0.52 | - | - | - | - | -2.74 |
|---|
| Net loss | -25 | -12 | -13 | 6 | -22 | -18 | -53 | -57 | -45 | -58 | -102 |
|---|
| Unrealized loss on available-for-sale securities, net of tax of $0 for periods presented | - | - | - | - | - | 0 | - | - | - | - | -0 |
|---|
| Comprehensive loss | - | -12 | -13 | 6 | -22 | -19 | -53 | -57 | -45 | -58 | -102 |
|---|